Comparison
BPC-157 vs Magnesium L-Threonate
Side-by-side of BPC-157 and Magnesium L-Threonate. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
Magnesium L-Threonate
Magnesium l-threonate (Magtein) crosses the blood-brain barrier. Typical dose 1,500-2,000 mg. Sleep and cognitive trial data, side effects.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
Magnesium L-Threonate
- •Distinct magnesium salt designed for blood-brain barrier penetration; not a higher-quality systemic magnesium
- •Liu 2010 rodent study: elevated CSF magnesium ~15% and increased hippocampal synaptic density
- •Trial portfolio in humans is small and mostly Magtein-funded; cognitive effects are modest where reported
- •Typical dose 1500 to 2000 mg/day delivers only ~108 to 144 mg of elemental magnesium
- •GI tolerability comparable to other magnesium forms; loose stools in a minority at 2000 mg/day
- •Distinct from magnesium glycinate, which is the conventional sleep/anxiety/repletion form
Side-by-side
| Attribute | BPC-157 | Magnesium L-Threonate |
|---|---|---|
| Category | peptide | supplement |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | Mg-T, MgT, Magtein, magnesium threonate |
| Half-life (hr) ↗ | 4 | 4 |
| Typical dose (mg) ↗ | 0.25 | 2000 |
| Dosing frequency | daily (anecdotal protocols) | 1 to 3 times daily |
| Routes | subcutaneous, intramuscular, oral | oral |
| Onset (hr) | - | 1 |
| Peak (hr) | - | 2 |
| Molecular weight | - | 294.5 |
| Molecular formula | C62H98N16O22 | C8H14MgO10 |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | Proposed to deliver magnesium across the blood-brain barrier more effectively than other oral salts via threonate-related transporters, raising CNS magnesium and modulating NMDA receptor function and synaptic plasticity. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | OTC dietary supplement |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | OTC supplement (not scheduled) |
| Pregnancy | Insufficient data | Standard magnesium safety; Mg-T-specific data limited |
| CAS | 137525-51-0 | 778571-57-6 |
| PubChem CID | 9941957 | 10691810 |
| Wikidata | Q4835418 | Q27151568 |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
Magnesium L-Threonate
Common side effects
- loose stools
- mild GI upset
- headache (rare)
- fatigue (rare)
Contraindications
- severe renal impairment (eGFR below 30)
- hypermagnesemia
- myasthenia gravis (high doses)
- concurrent IV magnesium therapy
Interactions
- tetracyclines and fluoroquinolones: magnesium chelation reduces antibiotic absorption; separate by 2 to 4 hours(moderate)
- bisphosphonates: reduced absorption; separate by 2 hours minimum(moderate)
- muscle relaxants and aminoglycosides: potentiated neuromuscular blockade at high doses(moderate)
- antihypertensives: additive blood pressure reduction at high doses(minor)
Which Should You Take?
Magnesium L-Threonate comes out ahead for most readers on the criteria we weight: 2 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is post-training recovery, pick BPC-157.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is focus or working memory, pick Magnesium L-Threonate.
- → If your priority is sleep onset or sleep quality, pick Magnesium L-Threonate.
Edge case: If you want to avoid research-only / gray-market sourcing, Magnesium L-Threonate is the more accessible choice.
Default choice: Magnesium L-Threonate. Lower friction to source, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and Magnesium L-Threonate?
BPC-157 and Magnesium L-Threonate differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or Magnesium L-Threonate?
BPC-157 half-life is 4 hours; Magnesium L-Threonate half-life is 4 hours.
Can you stack BPC-157 with Magnesium L-Threonate?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper